Company Description
Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health.
It's product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosi.
The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures.
Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018.
The company was incorporated in 2007 and is based in Jupiter, Florida.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | David L. Barthel M.B.A. |
Contact Details
Address: 555 Heritage Drive, Suite 205 Jupiter, Florida 33458 United States | |
| Phone | 561-935-9955 |
| Website | marizyme.com |
Stock Details
| Ticker Symbol | MRZM |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001413754 |
| CUSIP Number | 570372102 |
| ISIN Number | US5703721028 |
| Employer ID | 82-5464863 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David L. Barthel M.B.A. | Chief Executive Officer, Secretary and Director |
| Dr. Catherine J. Pachuk Ph.D. | Executive Vice President and Chief Scientific Officer |
| George Kovalyov C.A., CPA | Chief Financial Officer and Treasurer |
| Dr. Claudio Rigatto M.D. | Chief Medical Officer of My Health Logic |
| Kari Jacobson | Controller |
| Harrison Albert Ross C.F.A. | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 28, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 13, 2024 | 10-K | Annual Report |
| May 6, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 6, 2024 | 424B3 | Prospectus |
| Feb 6, 2024 | 8-K | Current Report |
| Dec 29, 2023 | 424B3 | Prospectus |
| Dec 28, 2023 | 8-K | Current Report |
| Nov 22, 2023 | 424B3 | Prospectus |